If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.28    -0.03 (-2.33%)
Bid:
1.23
Ask:
1.29
Spread: 0.06 (4.878%)
Market Cap: £30.03m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Product Launch

16 Dec 2005 07:00

Provexis PLC16 December 2005 PROVEXIS PLC ("Provexis" or the "Company") UK Launch of Sirco(TM) Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, is delighted to confirm the launch of itsSirco(TM) heart health juice drink in the UK in January 2006. The Company has so far secured an initial distribution base with two of the fivelargest supermarket retailers in the UK, which for reasons of commercialconfidentiality cannot be named at present. Both retailers will distributeSirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)will be initially available in premier stores which represent, by weighteddistribution, approximately 35 per cent. of their total UK distribution base.Within the second supermarket chain, Sirco(TM) will be initially available, byweighted distribution, across 70 per cent. of their total UK distribution base.Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,Apple & Blueberry and Orange, and the drink will be located in the chilled fruitjuice section. The Company is in on-going discussions with a number of other retailers andhopes to make further distribution announcements in 2006. In addition to the onelitre packs, the Company is also developing a 250ml bottle of Sirco(TM) fordistribution to retailers in mid 2006. This bottle will have an extended shelflife and is intended to widen the distribution base to include independentchemists, convenience stores and food service industry channels such as health,education and travel outlets. Sirco(TM) is the first heart health product to contain the patentedFruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order tohelp regular "healthy" consumers reduce the risk of heart attack and stroke. Thenatural bioactive works by reducing blood platelet aggregation ("thinning theblood"), a significant contributing factor to a thrombosis (internal bloodclot). Sirco(TM) carries the health claim "Helps to Maintain a Healthy Heart andBenefits Circulation" and is approved by the leading heart health charity, HEARTUK. Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said: "This marks a significant milestone for Provexis and we are delighted that wehave secured distribution with two of the largest UK supermarkets. Bothretailers are ideal outlets in terms of the demographics and target market forthis product. We will be investing in media advertising as well as in-storeactivity to ensure we maximise this substantial opportunity. We look forward to growing the retailer base for Sirco(TM) throughout 2006,whilst in parallel securing licensing arrangements with major international foodpartners to integrate the FruitFlow(TM) technology into new food products inglobal markets." For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Jul 20127:00 amRNSFinal Results
27th Jul 20127:00 amRNSNotice of Results
31st May 20127:00 amRNSTotal Voting Rights
17th May 20127:00 amRNSDraw Down of Funds and Issue of Equity
24th Apr 20127:00 amRNSScience in Sport brand relaunch
23rd Apr 20124:31 pmRNSAdditional Listing
2nd Apr 20127:00 amRNSDirectorate Change
30th Mar 201211:46 amRNSTotal Voting Rights Update
30th Mar 20127:00 amRNSPre-Close Update
16th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20124:40 pmRNSSecond Price Monitoring Extn
12th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20127:00 amRNSScience in Sport Update
14th Feb 20127:00 amRNSFruitflow update
9th Jan 20124:40 pmRNSSecond Price Monitoring Extn
9th Jan 20124:35 pmRNSPrice Monitoring Extension
9th Jan 20127:00 amRNSProvexis to fuel GB rowing team
7th Dec 20113:01 pmRNSAdditional Listing
1st Dec 20117:00 amRNSChange of adviser
1st Dec 20117:00 amRNSInterim Results
28th Nov 20117:00 amRNSNotice of Interim Results
8th Nov 20117:00 amRNSRenewal of £25 million Equity Financing Facility
24th Aug 20113:24 pmRNSResult of AGM
24th Aug 20117:00 amRNSAGM Statement
8th Aug 20114:40 pmRNSSecond Price Monitoring Extn
8th Aug 20114:35 pmRNSPrice Monitoring Extension
4th Aug 20114:40 pmRNSSecond Price Monitoring Extn
4th Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20115:22 pmRNSNotice of AGM
29th Jul 20117:00 amRNSTotal Voting Rights
26th Jul 20114:46 pmRNSResult of open offer
15th Jul 20114:35 pmRNSHolding(s) in Company
14th Jul 201110:44 amRNSHolding(s) in Company
12th Jul 20114:23 pmRNSHolding(s) in Company
12th Jul 20119:17 amRNSHolding(s) in Company
11th Jul 20111:42 pmRNSChange of Registered Office
5th Jul 20117:00 amRNSOpen Offer
30th Jun 20114:55 pmRNSHolding(s) in Company
30th Jun 20117:00 amRNSTotal Voting Rights
28th Jun 20113:34 pmRNSHolding(s) in Company
24th Jun 201112:08 pmRNSCompletion of the acquisition of SiS
20th Jun 20119:36 amRNSDirector Dealing
17th Jun 20114:15 pmRNSGrant of Options
17th Jun 20117:00 amRNSFinal Results
17th Jun 20117:00 amRNSAcquisition of Science in Sport Ltd
1st Jun 20117:00 amRNSUpdate on Crohn's disease trial
1st Jun 20117:00 amRNSAppointment of New Product Director
1st Jun 20117:00 amRNSSigning of Development Agreement
31st Mar 20117:00 amRNSPre-close update
28th Feb 20118:49 amRNSDevelopment Agreement - Replacement announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.